Clinically, autologous tumor-derived gp96 has been administered subcutaneously for the therapeutic development of anti-tumor immunity in patients with melanoma, renal cell carcinoma and glioblastoma37–39. This evidence concerns the gene HSP90B1 and renal cell carcinoma.